drugset / Trial / NCT05979220
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the efficacy and safety of Dalpiciclib combined with Letrozole in the maintenance treatment of HR positive and HER2 negative metastatic breast cancer after first-line chemotherapy.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2024-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 150 mg | Oral |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |